Nuvation Bio (NUVB) Revenue & Revenue Breakdown
Nuvation Bio Revenue Highlights
Latest Revenue (Y)
$62.90M
Latest Revenue (Q)
$13.12M
Main Segment (Y)
License
Main Geography (Y)
JAPAN
Nuvation Bio Revenue by Period
Nuvation Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $62.90M | 698.96% |
| 2024-12-31 | $7.87M | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Nuvation Bio generated $62.90M in revenue during NA 2025, up 698.96% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Nuvation Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $13.12M | 171.47% |
| 2025-06-30 | $4.83M | 56.71% |
| 2025-03-31 | $3.08M | -46.00% |
| 2024-12-31 | $5.71M | 685.56% |
| 2024-09-30 | $727.00K | -49.34% |
| 2024-06-30 | $1.44M | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $264.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
Nuvation Bio generated $13.12M in revenue during Q3 2025, up 171.47% compared to the previous quarter, and up 914.29% compared to the same period a year ago.
Nuvation Bio Revenue Breakdown
Nuvation Bio Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 |
|---|---|---|
| License | $38.24M | - |
| Product | $24.66M | - |
| License Revenue | - | $2.09M |
Nuvation Bio's latest annual revenue breakdown by segment (product or service), as of Dec 25: License (60.79%), and Product (39.21%).
Quarterly Revenue by Product
| Product/Service | Dec 25 | Jun 25 | Mar 25 |
|---|---|---|---|
| Product | $23.43M | $1.24M | - |
| License | $34.64M | $3.60M | - |
| Product Revenue | - | - | $779.00K |
| Royalty Revenue | - | - | $249.00K |
Nuvation Bio's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: License (59.66%), and Product (40.34%).
Nuvation Bio Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 25 | Dec 24 |
|---|---|---|
| CHINA | $9.41M | $5.20M |
| UNITED STATES | $24.70M | - |
| JAPAN | $28.83M | $2.70M |
Nuvation Bio's latest annual revenue breakdown by geography, as of Dec 25: JAPAN (45.80%), UNITED STATES (39.24%), and CHINA (14.95%).
Quarterly Revenue by Country
| Country | Dec 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 |
|---|---|---|---|---|---|
| UNITED STATES | $23.46M | $1.24M | - | - | - |
| JAPAN | $28.39M | $241.00K | $200.00K | $2.10M | $600.00K |
| CHINA | $3.11M | $3.40M | $2.90M | $5.10M | $100.00K |
Nuvation Bio's latest quarterly revenue breakdown by geography, as of Dec 25: JAPAN (51.65%), UNITED STATES (42.69%), and CHINA (5.66%).
Nuvation Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AUPH | Aurinia Pharmaceuticals | $283.06M | $73.47M |
| ABCL | AbCellera Biologics | $75.13M | $8.96M |
| VRDN | Viridian Therapeutics | $70.85M | $70.57M |
| NUVB | Nuvation Bio | $62.90M | $13.12M |
| OCUL | Ocular Therapeutix | $51.82M | $14.54M |
| QURE | uniQure | $16.10M | $3.70M |
| JANX | Janux Therapeutics | $10.00M | $10.00M |
| CLDX | Celldex Therapeutics | $1.54M | - |
| GPCR | Structure Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| VERA | Vera Therapeutics | - | - |